The recent academic activities of the Chinese sarcoma group
Establishment of the Targeted and Immunotherapy Working Group of the Chinese Anti-Cancer Association Sarcoma Committee
On June 7, 2025, the inaugural meeting of the Targeted and Immunotherapy Working Group of the Chinese Anti-Cancer Association Sarcoma Committee was successfully held in Shanghai. The meeting was chaired by Professor Jingnan Shen from the First Affiliated Hospital of Sun Yat-sen University.
Prof Shen delivered the opening remarks, emphasizing that the establishment of this working group marks an important milestone for the development of sarcoma targeted and immunotherapy in China. He expressed his hope that the group will strengthen multidisciplinary collaboration in both clinical and basic research, and promote innovation in treatment strategies.
During the meeting, the group’s objectives and future plans were presented, including organizing academic meetings, holding a clinical case competition, and developing a Chinese expert consensus on sarcoma targeted and immunotherapy.
The event concluded successfully, with participants expressing their commitment to advancing precision medicine for sarcoma and fostering closer collaboration among research institutions nationwide to improve patient outcomes.
“From Horizon to Sunrise” Sarcoma Research Symposium Convenes in Beijing, Showing Breakthroughs from Bench to Bedside
Co-hosted by People’s Medical Publishing House Co., Ltd. (PMPH) and the Beijing Association of Medical Laboratory Science, with support from the Sarcoma Committee of the Chinese Anti-Cancer Association, the “From Horizon to Sunrise: Advances in Basic and Clinical Research on Sarcoma” symposium was successfully held on July 25 and 26. The event brought together leading experts in bone tumor research to share cutting-edge findings, exchange clinical experience, and catalyze collaboration across disciplines.
ISOLS Board Member Prof. Xiaodong Tang opened the main symposium, welcoming distinguished participants and calling for open exchange to advance translational breakthroughs followed by Prof. Jingnan Shen from the first affiliated hospital of Sun Yat-sen University.
The horizon symbolizes the starting point of scientific exploration, while the sunrise embodies researchers’ steadfast hope to conquer disease and benefit patient, signaling the dawn of discovery. In sarcoma research, he emphasized, we must both ground our work in Chinese practical realities and stay aligned with global frontiers.
Bridging the gap between basic research and clinical practice to achieve true translational impact remains a shared challenge for all oncologists. He expressed the hope that this gathering would spark new ideas and illuminate the path forward. Prof. Sandra Strauss from UCL Cancer Institute shared experience of EURO-Ewing Group for improving clinical practice for Ewing sarcomas. Then the conferences focuses on AI-enabled multi-omics clinical pathway, single-cell insights into Ewing sarcoma and osteosarcoma, advances in liposomal irinotecan combinations and HER2-ADC in small round cell tumors, optimized regimens for advanced Ewing sarcoma and so on. All the panelists then engaged in a lively discussion.
In the closing address, Prof. Xiaodong Tang affirmed the symposium’s role in focusing the field on frontier therapies, practical surgical strategies, and high-value clinical experience. The meeting fostered an advanced platform for learning and exchange, invigorating discussion on key challenges in bone tumor care. “Diligent study and open exchange beget wisdom,” he noted—underscoring that continuous, practice-oriented dialogue is propelling sustained progress in sarcoma diagnosis and treatment. During the Gala dinner section, all the participants enjoyed and celebrated this event together.
CSCO Sarcoma Lecture Series Promotes Education in Sarcoma Diagnosis and Treatment
In 2025, the Chinese Society of Clinical Oncology (CSCO) Sarcoma Expert Committee organized more than five nationwide CSCO Sarcoma Lecture Series events to promote education and academic exchange in sarcoma diagnosis and treatment. The program was chaired by Prof. Jing Chen and Prof. Xiaohui Niu, bringing together experts and clinicians from major hospitals across China.
The lecture series covered a broad range of topics in musculoskeletal tumor management, including surgical treatment, chemotherapy, targeted therapy, immunotherapy, molecular diagnostics, and clinical evaluation. A strong emphasis was placed on multidisciplinary team (MDT) collaboration to enhance communication among surgeons, oncologists, pathologists, and radiologists.
Through thematic lectures, case discussions, and experience sharing, the series has provided practical and evidence-based guidance for clinicians. It serves as a key educational platform for advancing standardized and precise sarcoma care, fostering cooperation among institutions, and ultimately improving patient outcomes across China.